(Washington Post) Pfizer announced Tuesday that its maternal RSV vaccine, given during pregnancy, protected infants from developing severe symptoms during the first six months after birth — a critical window of vulnerability. The company plans to apply for approval of the vaccine before year’s end, with the hope that the shot could be the first vaccine to help protect infants against RSV — respiratory syncytial virus — as soon as next winter.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.